Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Ocuphire Pharma Inc (NQ: OCUP )

1.170 UNCHANGED
Last Price Updated: 4:00 PM EDT, Oct 23, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ocuphire Pharma Inc

< Previous 1 2 3 4 Next >
Ophthalmic Biopharmaceutical Ocuphire Pharma Shifts Focus To Gene Therapy Through Opus Genetics Stock Deal
Ocuphire Pharma acquires Opus Genetics, expanding its IRD gene therapy pipeline. The renamed company, Opus Genetics, will trade under "IRD" by late October 2024. 
Via Benzinga
Shareholder Alert: Ademi LLP Investigates Whether Ocuphire Pharma, Inc. Is Breaching Its Duties to Its Public Shareholders
From Ademi LLP
Via Business Wire
OCUP Stock Earnings: Ocuphire Pharma Misses EPS, Misses Revenue for Q2 2024
OCUP stock results show that Ocuphire Pharma missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024. 
Via InvestorPlace
These 3 Clinical-Stage Biotech Stocks Can Offer Exponential Gains
These biotech stocks, lacking in profitability but seeding huge potential, should be on your watchlist. 
Via Talk Markets
Duos Technologies And 2 Other Stocks Under $3 Insiders Are Buying
Via Benzinga
Recap: Ocuphire Pharma Q3 Earnings
Via Benzinga
A Look Into Healthcare Sector Value Stocks
Via Benzinga
Overview Of Value Stocks In The Healthcare Sector
Via Benzinga
Ocuphire Pharma Inc. (NASDAQ: OCUP) Highlighted for Surprising Price Action
Via Investor Brand Network
OCUP Stock Earnings: Ocuphire Pharma Misses EPS, Misses Revenue for Q1 2024
OCUP stock results show that Ocuphire Pharma missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. 
Via InvestorPlace
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Design Therapeutics And 2 Other Stocks Under $5 Insiders Are Buying
The Dow Jones index closed lower by over 150 points on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders... 
Via Benzinga
Topics Stocks
Exposures US Equities
OCUP Stock Earnings: Ocuphire Pharma Misses EPS, Misses Revenue for Q4 2023
OCUP stock results show that Ocuphire Pharma missed analyst estimates for earnings per share and missed on revenue for the fourth quarter of 2023. 
Via InvestorPlace
7 Under-the-Radar Biotech Stocks Gearing Up for Liftoff
Although the health innovation space can be a risky environment, undervalued biotech stocks can take some of the edge off. 
Via InvestorPlace
3 Value Stocks to Buy on the Dip: February 2024
While many investors continue to chase after the latest trends, these underappreciated value stocks to buy could be the true winners. 
Via InvestorPlace
Buy Alert: Analysts Say These 3 Growth Stocks Could Double in 2024
Often the best investments are out-of-favor and trade at silly cheap valuations. Check out three such growth stocks with huge upside. 
Via InvestorPlace
A Look Into Healthcare Sector Value Stocks
Via Benzinga
Overview Of Value Stocks In The Healthcare Sector
Via Benzinga
5 Value Stocks In The Healthcare Sector
Via Benzinga
Surprise! These 3 Penny Stocks Pack Powerful Financials.
While investing in penny stocks carries a rough reputation (to put it nicely), these speculative entities just might surprise you. 
Via InvestorPlace
Why Venus Concept Shares Are Trading Lower By Over 15%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers NeoGames S.A. (NASDAQ: NGMS) shares climbed 113.3% to $27.38 as the company agreed to be acquired by Aristocrat Leisure Limited for $29.50 per share in cash. 
Via Benzinga
The 7 Best Stocks Under $10 to Buy in May
While quality matters in the market, these best stocks under $10 to buy gives you some potential diamonds in the rough. 
Via InvestorPlace
7 Small-Cap Biotech Stocks with Massive Potential
Although small-cap biotech stocks present high risks, if they hit one out of the park, the rewards can be astronomical. 
Via InvestorPlace
Ocuphire Pharma Plunges Following CEO Termination, New Appointment: The Bull, Bear Case
Ocuphire Pharma Inc (NASDAQ: OCUP) was plunging over 22% at one point on Friday after the company announced it appointed Rick Rodgers to the role of interim CEO. 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Why SAP Shares Are Trading Higher By Around 6%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Gainers Mangoceuticals, Inc. (NASDAQ: MGRX) shares jumped 207% to $2.84. The company announced Thursday, that it's featured on Webull Corporate Communications Service Platform. 
Via Benzinga
US Stocks Mostly Lower; Nasdaq Down 50 Points
U.S. stocks traded mostly lower this morning, with the Nasdaq Composite dropping around 50 points on Friday. Following the market opening Friday, the Dow traded down 0.03% to 33,777.38 while the NASDAQ... 
Via Benzinga
7 Thrilling Biotech Stocks for Aggressive Investors to Buy
Amid the noise of the global markets recently, these speculative biotech stocks to buy might trade with a mind of their own. 
Via InvestorPlace
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Ocuphire Pharma, Inc. (NASDAQ: OCUP) Featured in Coverage of The MicroCap Rodeo’s 3rd Annual Winter Wonderful and Best Ideas Investor Conference
Via Investor Brand Network
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback